Alyeska Investment Group, L.P. Incyte Corp Transaction History

Alyeska Investment Group, L.P.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$70.23 - $86.01 $10.5 Million - $12.9 Million	150,000 New	150,000 $10.8 Million
Q3 2018 Nov 14, 2018	BUY	$61.75 - $74.23 $8.81 Million - $10.6 Million	142,689 Added 1951.7%	150,000 $10.4 Million
Q2 2018 Aug 14, 2018	SELL	$60.85 - $83.98 $14.9 Million - $20.5 Million	-244,165 Reduced 97.09%	7,311 $490,000
Q1 2018 May 15, 2018	SELL	$83.06 - $100.98 $370,198 - $450,067	-4,457 Reduced 1.74%	251,476 $21 Million
Q4 2017 Feb 14, 2018	SELL	$93.56 - $116.6 $4.17 Million - $5.19 Million	-44,533 Reduced 14.82%	255,933 $24.2 Million
Q3 2017 Nov 14, 2017	BUY	$109.15 - $138.27 $32.8 Million - $41.5 Million	300,466	300,466 $35.1 Million

644

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16.6B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Alyeska Investment Group, L.P., based on Form 13F filings with the SEC.

Stay updated on Alyeska Investment Group, L.P. with notifications on news.